Immix Biopharma, Inc. (IMMX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Immix Biopharma, Inc. (IMMX) Bundle
Looking to assess the intrinsic value of Immix Biopharma, Inc.? Our (IMMX) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | -89.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -.8 | -.5 | -1.3 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | -0.00238502 | 100 | 80 | 80 | 80 | 80 | 80 |
EBIT | -.8 | -.5 | -1.4 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Total Cash | .7 | .4 | 17.6 | 13.4 | 17.5 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .1 | .0 | .3 | 1.2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | -0.28565 | 100 | 79.94 | 79.94 | 79.94 | 79.94 | 79.94 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | .2 | .3 | .1 | .1 | 1.4 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | -0.15983 | 100 | 79.97 | 79.97 | 79.97 | 79.97 | 79.97 |
Capital Expenditure | .0 | .0 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 |
EBITAT | -.9 | -.5 | -1.4 | -8.2 | -16.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -.8 | -.4 | -1.4 | -8.5 | -15.7 | -.3 | .0 | .0 | .0 | .0 |
WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
PV UFCF | ||||||||||
SUM PV UFCF | -.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | 0 | |||||||||
Net Debt | -18 | |||||||||
Equity Value | 17 | |||||||||
Diluted Shares Outstanding, MM | 17 | |||||||||
Equity Value Per Share | 1.00 |
What You Will Get
- Real Immix Biopharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Immix Biopharma, Inc. (IMMX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Immix Biopharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to Immix Biopharma, Inc. (IMMX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for your financial assessments.
Key Features
- Comprehensive IMMX Data: Pre-filled with Immix Biopharma's historical financials and future growth projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investment plans.
- Adaptive Valuation Framework: Instant updates to Net Present Value (NPV) and intrinsic value based on your tailored inputs.
- Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and suitable for both industry veterans and newcomers.
How It Works
- Download: Get the comprehensive Excel file featuring Immix Biopharma, Inc.'s (IMMX) financial data.
- Customize: Tailor your forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate outcomes immediately.
- Make Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose This Calculator for Immix Biopharma, Inc. (IMMX)?
- Designed for Industry Experts: A sophisticated tool tailored for biopharma analysts, investors, and researchers.
- Comprehensive Data: Immix Biopharma’s historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically calculates intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the calculation process.
Who Should Use This Product?
- Investors: Accurately assess Immix Biopharma’s fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immix Biopharma, Inc. (IMMX).
- Consultants: Efficiently customize the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biopharma companies.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the life sciences field.
What the Immix Biopharma, Inc. (IMMX) Template Contains
- Comprehensive DCF Model: Editable template featuring in-depth valuation calculations tailored for biopharmaceutical analysis.
- Real-World Data: Immix Biopharma’s historical and projected financials preloaded for thorough examination.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns to provide deeper insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to the biopharma sector.
- Dashboard with Visual Outputs: Interactive charts and tables for clear, actionable insights.